These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36372933)

  • 1. Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.
    Faraj P; Hermansen A; Molden E; Hole K
    Ther Drug Monit; 2022 Dec; 44(6):720-728. PubMed ID: 36372933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined effect of CYP2C19 and CYP2D6 genotypes on escitalopram serum concentration and its metabolic ratio in a European patient population.
    Faraj P; Haslemo T; Tran JP; Stingl J; Molden E; Hole K
    Br J Clin Pharmacol; 2024 Oct; 90(10):2630-2637. PubMed ID: 38925553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
    Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
    J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression.
    Tsuchimine S; Ochi S; Tajiri M; Suzuki Y; Sugawara N; Inoue Y; Yasui-Furukori N
    Ther Drug Monit; 2018 Jun; 40(3):356-361. PubMed ID: 29570504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of
    Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
    Kumar Y; Kung S; Shinozaki G
    J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
    He Q; Mei Y; Liu Y; Yuan Z; Zhang J; Yan H; Shen L; Zhang Y
    J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
    Islam F; Marshe VS; Magarbeh L; Frey BN; Milev RV; Soares CN; Parikh SV; Placenza F; Strother SC; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
    Transl Psychiatry; 2022 Sep; 12(1):366. PubMed ID: 36068210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age of onset for increased dose-adjusted serum concentrations of antidepressants and association with sex and genotype: An observational study of 34,777 individuals.
    Tveit K; Hermann M; Nilsen RM; Wallerstedt SM; Rongve A; Molden E; Hole K
    Eur J Clin Pharmacol; 2024 Mar; 80(3):435-444. PubMed ID: 38197945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.
    Hole K; Haslemo T; Molden E
    Ther Drug Monit; 2023 Oct; 45(5):683-688. PubMed ID: 37012633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
    Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB; Wensing G; Kuhlmann J
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
    Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
    J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
    Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
    Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
    Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
    Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M; Tybring G; Dahl ML; Lindh JD
    Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
    Jukić MM; Haslemo T; Molden E; Ingelman-Sundberg M
    Am J Psychiatry; 2018 May; 175(5):463-470. PubMed ID: 29325448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.